Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
<h4>Background</h4>We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0206838 |
| _version_ | 1818905152485064704 |
|---|---|
| author | Edna O Viegas Arne Kroidl Patricia J Munseri Marco Missanga Charlotta Nilsson Nelson Tembe Asli Bauer Agricola Joachim Sarah Joseph Philipp Mann Christof Geldmacher Sue Fleck Wolfgang Stöhr Gabriella Scarlatti Said Aboud Muhammad Bakari Leonard Maboko Michael Hoelscher Britta Wahren Merlin L Robb Jonathan Weber Sheena McCormack Gunnel Biberfeld Ilesh V Jani Eric Sandström Eligius Lyamuya TaMoVac study group |
| author_facet | Edna O Viegas Arne Kroidl Patricia J Munseri Marco Missanga Charlotta Nilsson Nelson Tembe Asli Bauer Agricola Joachim Sarah Joseph Philipp Mann Christof Geldmacher Sue Fleck Wolfgang Stöhr Gabriella Scarlatti Said Aboud Muhammad Bakari Leonard Maboko Michael Hoelscher Britta Wahren Merlin L Robb Jonathan Weber Sheena McCormack Gunnel Biberfeld Ilesh V Jani Eric Sandström Eligius Lyamuya TaMoVac study group |
| author_sort | Edna O Viegas |
| collection | DOAJ |
| description | <h4>Background</h4>We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein adjuvanted with Glucopyranosyl Lipid A (GLA-AF) in volunteers from Tanzania and Mozambique.<h4>Methods</h4>Healthy HIV-uninfected adults (N = 191) were randomized twice; first to one of three HIV-DNA intradermal priming regimens by needle-free ZetaJet device at weeks 0, 4 and 12 (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL [3mg/mL] plus EP, Group III: 1x0.1mL [6mg/mL] plus EP). Second the same volunteers received 108 pfu HIV-MVA twice, alone or combined with CN54rgp140/GLA-AF, intramuscularly by syringe, 16 weeks apart. Additionally, 20 volunteers received saline placebo.<h4>Results</h4>Vaccinations and electroporation did not raise safety concerns. After the last vaccination, the overall IFN-γ ELISpot response rate to either Gag or Env was 97%. Intradermal electroporation significantly increased ELISpot response rates to HIV-DNA-specific Gag (66% group I vs. 86% group II, p = 0.026), but not to the HIV-MVA vaccine-specific Gag or Env peptide pools nor the magnitude of responses. Co-administration of rgp140/GLA-AF with HIV-MVA did not impact the frequency of binding antibody responses against subtype B gp160, C gp140 or E gp120 antigens (95%, 99%, 79%, respectively), but significantly enhanced the magnitude against subtype B gp160 (2700 versus 300, p<0.001) and subtype C gp140 (24300 versus 2700, p<0.001) Env protein. At relatively low titers, neutralizing antibody responses using the TZM-bl assay were more frequent in vaccinees given adjuvanted protein boost.<h4>Conclusion</h4>Intradermal electroporation increased DNA-induced Gag response rates but did not show an impact on Env-specific responses nor on the magnitude of responses. Co-administration of HIV-MVA with rgp140/GLA-AF significantly enhanced antibody responses. |
| first_indexed | 2024-12-19T21:18:47Z |
| format | Article |
| id | doaj.art-8aaff0f6894749a39798ad0d258c5204 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T21:18:47Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8aaff0f6894749a39798ad0d258c52042022-12-21T20:05:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011311e020683810.1371/journal.pone.0206838Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.Edna O ViegasArne KroidlPatricia J MunseriMarco MissangaCharlotta NilssonNelson TembeAsli BauerAgricola JoachimSarah JosephPhilipp MannChristof GeldmacherSue FleckWolfgang StöhrGabriella ScarlattiSaid AboudMuhammad BakariLeonard MabokoMichael HoelscherBritta WahrenMerlin L RobbJonathan WeberSheena McCormackGunnel BiberfeldIlesh V JaniEric SandströmEligius LyamuyaTaMoVac study group<h4>Background</h4>We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein adjuvanted with Glucopyranosyl Lipid A (GLA-AF) in volunteers from Tanzania and Mozambique.<h4>Methods</h4>Healthy HIV-uninfected adults (N = 191) were randomized twice; first to one of three HIV-DNA intradermal priming regimens by needle-free ZetaJet device at weeks 0, 4 and 12 (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL [3mg/mL] plus EP, Group III: 1x0.1mL [6mg/mL] plus EP). Second the same volunteers received 108 pfu HIV-MVA twice, alone or combined with CN54rgp140/GLA-AF, intramuscularly by syringe, 16 weeks apart. Additionally, 20 volunteers received saline placebo.<h4>Results</h4>Vaccinations and electroporation did not raise safety concerns. After the last vaccination, the overall IFN-γ ELISpot response rate to either Gag or Env was 97%. Intradermal electroporation significantly increased ELISpot response rates to HIV-DNA-specific Gag (66% group I vs. 86% group II, p = 0.026), but not to the HIV-MVA vaccine-specific Gag or Env peptide pools nor the magnitude of responses. Co-administration of rgp140/GLA-AF with HIV-MVA did not impact the frequency of binding antibody responses against subtype B gp160, C gp140 or E gp120 antigens (95%, 99%, 79%, respectively), but significantly enhanced the magnitude against subtype B gp160 (2700 versus 300, p<0.001) and subtype C gp140 (24300 versus 2700, p<0.001) Env protein. At relatively low titers, neutralizing antibody responses using the TZM-bl assay were more frequent in vaccinees given adjuvanted protein boost.<h4>Conclusion</h4>Intradermal electroporation increased DNA-induced Gag response rates but did not show an impact on Env-specific responses nor on the magnitude of responses. Co-administration of HIV-MVA with rgp140/GLA-AF significantly enhanced antibody responses.https://doi.org/10.1371/journal.pone.0206838 |
| spellingShingle | Edna O Viegas Arne Kroidl Patricia J Munseri Marco Missanga Charlotta Nilsson Nelson Tembe Asli Bauer Agricola Joachim Sarah Joseph Philipp Mann Christof Geldmacher Sue Fleck Wolfgang Stöhr Gabriella Scarlatti Said Aboud Muhammad Bakari Leonard Maboko Michael Hoelscher Britta Wahren Merlin L Robb Jonathan Weber Sheena McCormack Gunnel Biberfeld Ilesh V Jani Eric Sandström Eligius Lyamuya TaMoVac study group Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLoS ONE |
| title | Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. |
| title_full | Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. |
| title_fullStr | Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. |
| title_full_unstemmed | Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. |
| title_short | Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. |
| title_sort | optimizing the immunogenicity of hiv prime boost dna mva rgp140 gla vaccines in a phase ii randomized factorial trial design |
| url | https://doi.org/10.1371/journal.pone.0206838 |
| work_keys_str_mv | AT ednaoviegas optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT arnekroidl optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT patriciajmunseri optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT marcomissanga optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT charlottanilsson optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT nelsontembe optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT aslibauer optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT agricolajoachim optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT sarahjoseph optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT philippmann optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT christofgeldmacher optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT suefleck optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT wolfgangstohr optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT gabriellascarlatti optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT saidaboud optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT muhammadbakari optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT leonardmaboko optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT michaelhoelscher optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT brittawahren optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT merlinlrobb optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT jonathanweber optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT sheenamccormack optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT gunnelbiberfeld optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT ileshvjani optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT ericsandstrom optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT eligiuslyamuya optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign AT tamovacstudygroup optimizingtheimmunogenicityofhivprimeboostdnamvargp140glavaccinesinaphaseiirandomizedfactorialtrialdesign |